Literature DB >> 7525180

A new strategy for the treatment of inflammatory pain. Prevention or elimination of central sensitization.

C J Woolf1.   

Abstract

The optimal treatment of pain requires an understanding of the mechanisms involved. Pain is a sensory end-point that can be generated by a number of dissimilar processes. Consequently, the concept of treating pain as a unitary symptom is obsolete. The mechanisms responsible for specific types of pain need to be understood, and particular treatments should be aimed selectively at the various subtypes of pain. A major breakthrough in our understanding of pain has come from the appreciation that clinical pain is qualitatively quite different from physiological or nociceptive pain and is characterised by the appearance of abnormal hypersensitivity. Clinical pain is more than a reflection of sustained peripheral input and it is, to a large extent, the expression of changes produced in the CNS, including the phenomenon of central sensitization. We need to treat both the disease/injury process in the periphery and the changes it induces or triggers in the CNS. Prevention of central sensitization will substantially eliminate the hyperalgesia and allodynia that patients find so distressing, and it offers new possibilities for the development of novel analgesics or antihypersensitivity drugs.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7525180     DOI: 10.2165/00003495-199400475-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  67 in total

1.  Contribution of protein kinase C to central sensitization and persistent pain following tissue injury.

Authors:  T J Coderre
Journal:  Neurosci Lett       Date:  1992-06-22       Impact factor: 3.046

2.  Experimental evidence on the nature of cutaneous hyperalgesia.

Authors:  J D HARDY; H G WOLFF; H GOODELL
Journal:  J Clin Invest       Date:  1950-01       Impact factor: 14.808

3.  Rate of rise of the cumulative depolarization evoked by repetitive stimulation of small-caliber afferents is a predictor of action potential windup in rat spinal neurons in vitro.

Authors:  L G Sivilotti; S W Thompson; C J Woolf
Journal:  J Neurophysiol       Date:  1993-05       Impact factor: 2.714

4.  Small-caliber afferent inputs produce a heterosynaptic facilitation of the synaptic responses evoked by primary afferent A-fibers in the neonatal rat spinal cord in vitro.

Authors:  S W Thompson; C J Woolf; L G Sivilotti
Journal:  J Neurophysiol       Date:  1993-06       Impact factor: 2.714

5.  Pharmacological properties of a C-fibre response evoked by saphenous nerve stimulation in an isolated spinal cord-nerve preparation of the newborn rat.

Authors:  J C Nussbaumer; M Yanagisawa; M Otsuka
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

6.  The role of neurokinin and N-methyl-D-aspartate receptors in synaptic transmission from capsaicin-sensitive primary afferents in the rat spinal cord in vitro.

Authors:  I Nagy; C A Maggi; A Dray; C J Woolf; L Urban
Journal:  Neuroscience       Date:  1993-02       Impact factor: 3.590

7.  Presynaptic inhibitory action of enkephalin on excitatory transmission in superficial dorsal horn of rat spinal cord.

Authors:  Y Hori; K Endo; T Takahashi
Journal:  J Physiol       Date:  1992-05       Impact factor: 5.182

Review 8.  Generation of acute pain: central mechanisms.

Authors:  C J Woolf
Journal:  Br Med Bull       Date:  1991-07       Impact factor: 4.291

9.  Neurogenic hyperalgesia: central neural correlates in responses of spinothalamic tract neurons.

Authors:  D A Simone; L S Sorkin; U Oh; J M Chung; C Owens; R H LaMotte; W D Willis
Journal:  J Neurophysiol       Date:  1991-07       Impact factor: 2.714

10.  Evidence for a central component of post-injury pain hypersensitivity.

Authors:  C J Woolf
Journal:  Nature       Date:  1983 Dec 15-21       Impact factor: 49.962

View more
  12 in total

1.  Management of Inflammatory Pain with Selective COX-2 Inhibitors: Promises and Facts.

Authors: 
Journal:  Curr Rev Pain       Date:  1999

2.  The specialised pro-resolving lipid mediator maresin 1 reduces inflammatory pain with a long-lasting analgesic effect.

Authors:  Victor Fattori; Felipe A Pinho-Ribeiro; Larissa Staurengo-Ferrari; Sergio M Borghi; Ana C Rossaneis; Rubia Casagrande; Waldiceu A Verri
Journal:  Br J Pharmacol       Date:  2019-04-15       Impact factor: 8.739

Review 3.  Ketorolac for postoperative pain management in children.

Authors:  J B Forrest; E L Heitlinger; S Revell
Journal:  Drug Saf       Date:  1997-05       Impact factor: 5.606

Review 4.  Preclinical and clinical development of dexketoprofen.

Authors:  D Mauleón; R Artigas; M L García; G Carganico
Journal:  Drugs       Date:  1996       Impact factor: 9.546

Review 5.  Clinical pharmacokinetics of dexketoprofen.

Authors:  M J Barbanoj; R M Antonijoan; I Gich
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

6.  Sensitivity of repeated interdigital web pinching to detect antinociceptive effects of ibuprofen.

Authors:  J W Growcott; A Stone; R Beise; H Stammer; W Tetzloff; C Demey
Journal:  Br J Clin Pharmacol       Date:  2000-04       Impact factor: 4.335

7.  Spinal substance P receptor expression and internalization in acute, short-term, and long-term inflammatory pain states.

Authors:  P Honor; P M Menning; S D Rogers; M L Nichols; A I Basbaum; J M Besson; P W Mantyh
Journal:  J Neurosci       Date:  1999-09-01       Impact factor: 6.167

8.  The dose-related effects of paracetamol on hyperalgesia and nociception in the rat.

Authors:  M Bianchi; A E Panerai
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

Review 9.  The spinal actions of nonsteroidal anti-inflammatory drugs and the dissociation between their anti-inflammatory and analgesic effects.

Authors:  K McCormack
Journal:  Drugs       Date:  1994       Impact factor: 9.546

10.  Perceptual wind-up in the human oesophagus is enhanced by central sensitisation.

Authors:  S Sarkar; C J Woolf; A R Hobson; D G Thompson; Q Aziz
Journal:  Gut       Date:  2006-02-21       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.